Multiple Sclerosis Clinical Trial
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Summary
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
Full Description
This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301.
Eligibility Criteria
Key Inclusion Criteria:
Patient completed the ECU-NMO-301 trial
Patient has given written informed consent
Key Exclusion Criteria:
Patients who have withdrawn from the ECU-NMO-301 trial as a result of an AE related to trial drug
Female patients who are pregnant, breastfeeding, or intend to conceive during the course of the trial
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 56 Locations for this study
Scottsdale Arizona, 85259, United States
Oceanside California, 92056, United States
Washington District of Columbia, 20007, United States
Miami Florida, 33136, United States
Orlando Florida, 32806, United States
Fort Wayne Indiana, 46805, United States
Kansas City Kansas, 66160, United States
Nicholasville Kentucky, 40503, United States
Baltimore Maryland, 21287, United States
Rochester Minnesota, 55905, United States
Saint Louis Missouri, 63110, United States
New York New York, 10016, United States
New York New York, 10029, United States
Columbus Ohio, 43214, United States
Philadelphia Pennsylvania, 19104, United States
Pittsburgh Pennsylvania, 15232, United States
Dallas Texas, 75246, United States
San Antonio Texas, 78229, United States
Salt Lake City Utah, 84108, United States
Pilar Buenos Aires, B1629, Argentina
Rosario Santa Fe, S2000, Argentina
Ciudad Autonoma, Buenos Aires, , C1221, Argentina
Ciudad Autonoma, Buenos Aires , C1425, Argentina
Camperdown New South Wales, , Australia
Fitzroy Victoria, 3065, Australia
Ottawa Ontario, K1H 8, Canada
Floridablanca Santander, , Colombia
Zagreb , 10000, Croatia
Praha , , Czechia
Teplice , 415 0, Czechia
Arhus , 8000, Denmark
Heidelberg Baden Wuerttemberg, 69120, Germany
Munich Bayern, 81675, Germany
Dusseldorf Nordrhein Westfalen, 40225, Germany
Rostock , 18147, Germany
Shatin , , Hong Kong
Catania , 95123, Italy
Napoli , 80131, Italy
Padova , 35128, Italy
Rome , 00178, Italy
Chiba-shi Chiba-Ken, 260-8, Japan
Nishinomiya-shi HyogoKen, , Japan
Kyoto-shi Kyoto-Fu, 604-8, Japan
Sendai-shi Miyagi-Ken, 980-8, Japan
Ube-shi Yamaguchi-Ken, 755-8, Japan
Fukuoka , 812-8, Japan
Tokio , , Japan
Goyang-si Gyeonggi-do, 410-7, Korea, Republic of
Seoul , 11074, Korea, Republic of
Seoul , 135-7, Korea, Republic of
Seoul , 136-7, Korea, Republic of
Seoul , 136-7, Korea, Republic of
Kuching Sarawak, 93586, Malaysia
Kuala Lumpur , 50586, Malaysia
Kazan , 42002, Russian Federation
Krasnoyarsk , 66003, Russian Federation
Novosibirsk , 63006, Russian Federation
Rostov-on Don , , Russian Federation
Barakaldo Bizkaia, 48903, Spain
Cordoba , 14404, Spain
Madrid , 28040, Spain
Taipei , , Taiwan
Pathum Thani , , Thailand
Ankara , 06100, Turkey
Edirne , , Turkey
Izmir , 35340, Turkey
Kocaeli , , Turkey
Samsun , , Turkey
Liverpool , L97LJ, United Kingdom
How clear is this clinincal trial information?